Study of the Combination Carboplatin Plus Celecoxib in Heavily Pre-treated Recurrent Ovarian Cancer Patients (carbo-cox2)

This study has been completed.
Sponsor:
Information provided by:
Catholic University of the Sacred Heart
ClinicalTrials.gov Identifier:
NCT01124435
First received: May 14, 2010
Last updated: June 3, 2010
Last verified: December 2008

May 14, 2010
June 3, 2010
October 2003
September 2007   (final data collection date for primary outcome measure)
Efficacy of the Combination Carboplatin plus Celecoxib in Heavily Pre-treated Recurrent Ovarian Cancer Patients [ Time Frame: 48 months ] [ Designated as safety issue: Yes ]
The tumor response rate by Response Evaluation Criteria in Solid Tumors (RECIST) criteria and duration of response, progression-free survival (PFS), overall survival (OS), toxicity assessment, and quality of life (QoL) measures with carboplatin-celcoxib in heavly pretreated recurrent ovarian cancer patients.
Efficacy of the Combination Carboplatin plus Celecoxib in Heavily Pre-treated Recurrent Ovarian Cancer Patients [ Time Frame: 48 months ] [ Designated as safety issue: Yes ]
The tumor response rate by RECIST criteria and duration of response, progression-free survival (PFS), overall survival (OS), toxicity assessment, and QoL measures with carboplatin-celcoxib in heavly pretreated recurrent ovarian cancer patients.
Complete list of historical versions of study NCT01124435 on ClinicalTrials.gov Archive Site
The modulation of angiogenesis-related molecules with the combination celecoxib plus carboplatin in patients with recurrent, heavily pre-treated OC [ Time Frame: 12 months ] [ Designated as safety issue: Yes ]
Serum levels of vascular endothelial growth factor (VEGF) and endostatin evaluated in a preliminary series of 11 patients at baseline and after 1 month of carboplatin-celecoxib
The modulation of angiogenesis-related molecules with the combination celecoxib plus carboplatin in patients with recurrent, heavily pre-treated OC [ Time Frame: 12 months ] [ Designated as safety issue: Yes ]
Serum levels of VEGF and endostatin evaluated in a preliminary series of 11 patients at baseline and after 1 month of carboplatin-celecoxib
Not Provided
Not Provided
 
Study of the Combination Carboplatin Plus Celecoxib in Heavily Pre-treated Recurrent Ovarian Cancer Patients
Phase II Study of the Combination Carboplatin Plus Celecoxib in Heavily Pre-treated Recurrent Ovarian Cancer Patients

The aim of this study is to evaluate the antitumor activity and potential adverse effects of the combination celecoxib plus carboplatin in patients with recurrent, heavily pre-treated Ovarian Cancer (OC). The potential changes induced by the experimental combination on angiogenesis-related serum markers and quality of life measures will be also evaluated.The main objective is to evaluate the response rate. Secondary objectives are the following:toxicity;progression free survival;overall survival;duration of response;quality of life;modulation of angiogenesis-related molecules.

This phase II prospective study will be conducted at the Gynecologic Oncology Units of the Catholic University of Rome and Campobasso, Italy. The study is non-sponsored, investigators initiated. The primary objective is to determine the tumor response rate by RECIST criteria. Secondary objectives included duration of response, progression-free survival (PFS), overall survival (OS), toxicity assessment, and QoL measures.Patients are required to take celecoxib (200 mg tablets by mouth twice daily, day 1 to 28), associated to intravenous carboplatin (area under the curve (AUC) 5 over 30 to 60 minutes, every 28 days). Patients who will develop carboplatin hypersensitivity reaction (HSR) will follow a desensitization protocol, or alternatively will switch to cisplatin. Erythropoietic stimulating agent and myeloid growth factors are not permitted for cycle 1 of study treatment, and their use will be chosen by the treating physician, according to hospital policy.Treatment will be discontinued when any of the following events occurs: radiographic or clinical evidence of cancer progression; deterioration of health or intolerable toxicity; patient refusal. Before starting treatment, patients will be evaluated by medical history, physical examination, cell blood count (CBC), chemistry panel, Ca125, and either computed tomography or magnetic resonance imaging scan. The primary endpoint is to determine the overall response (OR) rate. Secondary endpoints include the assessment of duration of response, PFS, OS, toxicity events and QoL scores. When treatment will be discontinued, patients will receive a follow-up visit every 3 months

Interventional
Phase 2
Endpoint Classification: Safety/Efficacy Study
Intervention Model: Single Group Assignment
Masking: Open Label
Primary Purpose: Treatment
Ovarian Neoplasms
Drug: Carboplatin plus Celecoxib
celecoxib (200 mg tablets by mouth twice daily, day 1 to 28), associated to intravenous carboplatin (area under the curve (AUC) 5 over 30 to 60 minutes, every 28 days).
Not Provided
Ferrandina G, Lauriola L, Zannoni GF, Fagotti A, Fanfani F, Legge F, Maggiano N, Gessi M, Mancuso S, Ranelletti FO, Scambia G. Increased cyclooxygenase-2 (COX-2) expression is associated with chemotherapy resistance and outcome in ovarian cancer patients. Ann Oncol. 2002 Aug;13(8):1205-11.

*   Includes publications given by the data provider as well as publications identified by ClinicalTrials.gov Identifier (NCT Number) in Medline.
 
Completed
45
December 2008
September 2007   (final data collection date for primary outcome measure)

Inclusion Criteria:

  • Recurrent epithelial ovarian or fallopian tube or peritoneal serous carcinomas with measurable disease as assessed by Response Evaluation Criteria in Solid Tumors criteria
  • Patients will require to have received a platinum-containing regimen as primary treatment and at least one line of chemotherapy for recurrent disease
  • An interval time from the last platinum-based chemotherapy after 6months
  • 18 years of years
  • Eastern Cooperative Oncology Group performance status of 0 to 2
  • Adequate bone marrow
  • Adequate renal and hepatic functions
  • Written informed consent to the study protocol

Exclusion Criteria:

  • Hypersensitivity to celecoxib or aspirin or other nonsteroidal anti-inflammatory drugs or sulfonamides
  • Significant comorbidities including any active coronary artery disease requiring management or symptomatic congestive heart failure or bleeding diathesis or uncontrolled severe hypertension or active gastrointestinal ulcer within 12 months or chronic inflammatory bowel diseases or deep venous or arterial thrombosis within 12 months or history of pulmonary embolism
  • Concomitant use of possible interactive drugs
  • Surgery and chemotherapy or radiotherapy within 1 month
  • Actual or potential childbearing
  • Breast-feeding
  • Prior cancer treatment with a COX2 inhibitor
  • Any psychological and/or sociological or geographical condition potentially hampering compliance with the study protocol and follow-up schedule
Female
18 Years to 75 Years
No
Contact information is only displayed when the study is recruiting subjects
Italy
 
NCT01124435
935/03
Yes
Giovanni SCAMBIA-Department of Obstetrics and Gynecology-Catholic University of the Sacred Heart, Catholic University of the Sacred Heart
Catholic University of the Sacred Heart
Not Provided
Principal Investigator: Giovanni sCAMBIA, PhD Department of Obstetrics and Gynecology,
Catholic University of the Sacred Heart
December 2008

ICMJE     Data element required by the International Committee of Medical Journal Editors and the World Health Organization ICTRP